Cui Lianxu, Saeed Yasmeen, Li Haomin, Yang Jingli
Department of Neurosurgery, The First People's Hospital of Foshan, 81 North Lingnan Road, Foshan, Guangdong, 528300, PR China.
Guangdong VitaLife Biotechnology Co., LTD, 61 Xiannan Road, Nanhai District, Foshan, Guangdong, 528200, PR China.
Regen Med. 2022 Jan;17(1):37-53. doi: 10.2217/rme-2021-0069. Epub 2021 Dec 15.
Traumatic brain injury (TBI) is a serious health concern, yet there is a lack of standardized treatment to combat its long-lasting effects. The objective of the present study was to provide an overview of the limitation of conventional stem-cell therapy in the treatment of TBI and to discuss the application of novel acellular therapies and their advanced strategies to enhance the efficacy of stem cells derived therapies in the light of published study data. Moreover, we also discussed the factor to optimize the therapeutic efficiency of stem cell-derived acellular therapy by overcoming the challenges for its clinical translation. Hence, we concluded that acellular therapy possesses the potential to bring a breakthrough in the field of regenerative medicine to treat TBI.
创伤性脑损伤(TBI)是一个严重的健康问题,但目前缺乏标准化的治疗方法来对抗其长期影响。本研究的目的是概述传统干细胞疗法在治疗TBI方面的局限性,并根据已发表的研究数据,讨论新型无细胞疗法的应用及其先进策略,以提高干细胞衍生疗法的疗效。此外,我们还讨论了通过克服其临床转化面临的挑战来优化干细胞衍生无细胞疗法治疗效率的因素。因此,我们得出结论,无细胞疗法有潜力在再生医学领域为治疗TBI带来突破。
ACS Chem Neurosci. 2020-7-15
Stem Cell Res Ther. 2023-8-8
Behav Brain Res. 2018-3-15
Clin Neurol Neurosurg. 2024-4
Cell Mol Neurobiol. 2023-3